Skip to main content
OpenTrials

Clinical trial condition

Carcinoma, Non-Small-Cell Lung

Explore clinical trials studying Carcinoma, Non-Small-Cell Lung. Study availability and eligibility vary by location and protocol.

4,704 public trials 1,044 recruiting studies
Refine in advanced search Browse all conditions

Carcinoma, Non-Small-Cell Lung trial results

Completed

Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008)

NCT03976375

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +9 more
Locations
  • Comprehensive Blood & Cancer Center [Bakersfield, CA] ( Site 1604) Bakersfield, California, United States
  • Cancer Specialists of North Florida - Fleming Island ( Site 1675) Fleming Island, Florida, United States
  • Mid-Florida Cancer Centers ( Site 1611) Orange City, Florida, United States
  • University of Kentucky School of Medicine & Hospitals ( Site 1621) Lexington, Kentucky, United States
View all 143 locations
View Trial Details
Completed

Pembrolizumab/Vibostolimab Coformulation (MK-7684A) or Pembrolizumab/Vibostolimab Coformulation Plus Docetaxel Versus Docetaxel for Metastatic Non Small Cell Lung Cancer (NSCLC) With Progressive Disease After Platinum Doublet Chemotherapy and Immunotherapy (MK-7684A-002, KEYVIBE-002)

NCT04725188

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +9 more
Locations
  • Cedars-Sinai Medical Center ( Site 2522) Los Angeles, California, United States
  • Illinois Cancer Care ( Site 2534) Peoria, Illinois, United States
  • Baptist Health Lexington-Research ( Site 2502) Lexington, Kentucky, United States
  • University of Maryland ( Site 2528) Baltimore, Maryland, United States
View all 95 locations
View Trial Details
Completed

Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies

NCT03126110

Conditions
Adenocarcinoma, Adenoma, Adnexal Diseases, +82 more
Locations
  • The Angeles Clinic and Research Institute Los Angeles, California, United States
  • University of Florida Gainesville, Florida, United States
  • Karmanos Cancer Institute Detroit, Michigan, United States
  • Washington University - Siteman Cancer Center St Louis, Missouri, United States
View all 38 locations
View Trial Details
Completed

The Watch the Spot Trial

NCT02623712

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +9 more
Locations
  • Kaiser Permanente Southern California Pasadena, California, United States
View Trial Details
Completed

Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer

NCT02475213

Conditions
Bronchial Neoplasms, Carcinoma, Carcinoma, Bronchogenic, +24 more
Locations
  • Mayo Clinic - AZ Scottsdale, Arizona, United States
  • Christiana Care Health Services, Inc. Newark, Delaware, United States
  • Mayo Clinic - FL Jacksonville, Florida, United States
  • Moffitt Cancer Center Tampa, Florida, United States
View all 20 locations
View Trial Details
Completed

Study to Evaluate CCS1477 in Advanced Tumours

NCT03568656

Conditions
Advanced Solid Tumors, Breast Diseases, Breast Neoplasms, +15 more
Locations
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
  • Thomas Jefferson University, Sidney Kimmel Cancer Center Philadelphia, Pennsylvania, United States
  • Institute Bergonie Bordeaux, France
  • Hôpital Europeen Georges Pompidou Paris, France
View all 19 locations
View Trial Details

Related conditions